July 14, 2008

 

Press Release no.1

NSE completes its 2103rd Normal Settlement

 

The Exchange has successfully completed its 2103RD Normal Settlement (Rolling T+2 following SEBI directive) since inception i.e., Settlement Numbers N – 2008131 on July 14, 2008. The settlement statistics is as follows:          

Particulars
Values

 

N – 2008131

Total traded quantity (lakhs)

5384.03

Total traded value (Rs. In Crores)

11402.31

Total value of the settlement (Securities) (Rs. In Crores)

1981.75

Total value of the settlement (Funds) (Rs. In Crores)

621.01

Shortages for the settlement

0.24%

% of  Delivery ( No. of shares deliverable / No. of shares traded )

15.92%

 

Retail Debt Market have completed its 1377th settlement detail of which is as follows:

 

Settlement No.

Traded Value

Settlement Value

 

 

Securities

Funds

D- 2008131

NIL

NIL

NIL

 

Press Release no.2

News about Apollo Sindhoori Capital Investments Limited

 

The media had reports that the Aditya Birla group may buy Apollo Sindhoori Capital Investments Limited for around Rs. 260-280 crores.

 

The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company.

 

Apollo Sindhoori Capital Investments Limited has vide its letter inter-alia stated, "The Board of Directors at their meeting held on 29th October 2007 proposed to bring in additional investment either through strategic/financial investor. Towards this the company is in discussion with potential strategic/financial investors including A V Birla. As of now the Company has not firmed up and no agreement has been reached. As and when any development takes place, the Company will intimate the Stock Exchange."

 

Press Release no.3

News about Ranbaxy Laboratories Ltd

 

The media had reports that the US department of justice has levelled adulteration charges against Ranbaxy Laboratories Ltd.

 

The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company.

 

Ranbaxy Laboratories Ltd has vide its letter inter-alia stated, "We wish to inform you that, 1) The Government of the United States of America ("the Government") has filed a Motion before the US District Court in the District of Maryland (Southern Division) requesting that the company be directed to produce all reports concerning Audits conducted by PAREXEL Consulting and related documents ("the PARAXEL Audit documents") in the context of an ongoing investigation ("the Investigation") by the Government concerning possible violations of Federal laws pertaining to failure to comply with Federal Statutes and Regulations. 2) Even before the Motion was filed, the company had assured the Government that it would provide the PARAXEL Audit documents to it notwithstanding the Client-Attorney-Privilege attached thereto. 3) In the Motion, the Government has made certain references to allegations concerning possible violations of Federal laws (the "allegations") in relation to the Investigation. 4) The Company denies the allegations and asserts that it has not committed any wrongdoing. 5) The Government has not brought any charges against the Company. 6) The Company continues to provide full cooperation to the Government in regard to the Investigation".